The radiosensitising effects of Iressa (ZD 1839), an epidermal growth factor receptor tyrosine kinase inhibitor, on related bladder cancer cell lines in vitro

被引：0
|
作者：
Maddineni, SB
Sangar, V
Margison, GP
Hendry, JH
Betts, CD
O'Flynn, KJ
Clarke, NW
机构：
来源：
JOURNAL OF UROLOGY | 2003年 / 169卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
520
引用
收藏
页码：135 / 135
页数：1
相关论文
共 50 条
  • [31] A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients
    Daneshmand, M
    Parolin, DAE
    Hirte, HW
    Major, P
    Goss, G
    Stewart, D
    Batist, G
    Miller, WH
    Matthews, S
    Seymour, L
    Lorimer, IAJ
    CLINICAL CANCER RESEARCH, 2003, 9 (07) : 2457 - 2464
  • [32] Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa®)
    Burdak-Rothkamm, S
    Rübe, CE
    Nguyen, TP
    Ludwig, D
    Feldmann, K
    Wiegel, T
    Rübe, C
    STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 (03) : 197 - 204
  • [33] Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
    Ciardiello, F
    Caputo, R
    Bianco, R
    Damiano, V
    Pomatico, G
    De Placido, S
    Bianco, AR
    Tortora, G
    CLINICAL CANCER RESEARCH, 2000, 6 (05) : 2053 - 2063
  • [34] Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (iressa)
    Bianco, C
    Tortora, G
    Bianco, R
    Caputo, R
    Veneziani, BM
    Caputo, R
    Damiano, V
    Troiani, T
    Fontanini, G
    Raben, D
    Pepe, S
    Bianco, AR
    Ciardiello, F
    CLINICAL CANCER RESEARCH, 2002, 8 (10) : 3250 - 3258
  • [35] Activity of the epidermal growth factor receptor inhibitor gefitinib ('Iressa', ZD1839) in refractory non-small-cell lung cancer
    Parra, HS
    Cavina, R
    Zucali, P
    Campagnoli, E
    Latteri, F
    Biancofiore, G
    Abbadessa, G
    Morenghi, E
    Santoro, A
    BRITISH JOURNAL OF CANCER, 2003, 89 : S33 - S33
  • [36] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors
    Blackledge, G
    Averbuch, S
    BRITISH JOURNAL OF CANCER, 2004, 90 (03) : 566 - 572
  • [37] ZD1839 ('Iressa') inhibits the growth response of bladder tumour cell lines to Epidermal Growth Factor and the induction of TIMP1
    Nutt, JE
    Mellon, JK
    Lunec, J
    BRITISH JOURNAL OF CANCER, 2001, 85 : 53 - 53
  • [38] Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer
    Shintani, S
    Li, CN
    Mihara, M
    Terakado, N
    Yano, J
    Nakashiro, K
    Hamakawa, H
    INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (06) : 1030 - 1037
  • [39] Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
    G Blackledge
    S Averbuch
    British Journal of Cancer, 2004, 90 : 566 - 572
  • [40] The effect on nasopharyngeal carcinoma by ZD1839, an epidermal growth factor receptor-selective tyrosine kinase inhibitor
    Guan, Zhong-Zhen
    Wang, Shu-Sen
    ANNALS OF ONCOLOGY, 2004, 15 : 141 - 141
12345